Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influenza Vaccine Feasibility Study in Children With Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02967393
Recruitment Status : Completed
First Posted : November 18, 2016
Results First Posted : April 23, 2018
Last Update Posted : April 23, 2018
Sponsor:
Collaborators:
Centers for Disease Control and Prevention
Duke University
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Kathryn Edwards, Vanderbilt University Medical Center

Brief Summary:
This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients in this study will receive the FLUARIX® influenza vaccine, while the other half will receive a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as a surrogate for LAIV4.

Condition or disease Intervention/treatment Phase
Asthmatic Drug: ccIIV4 Drug: IIV4 Phase 4

Detailed Description:

The association of an increased risk in wheezing following receipt of a live-attenuated influenza vaccine in children at least 2 years of age with a prior history of asthma or wheeze remains unclear.

The Centers for Disease Control (CDC) and Prevention's Clinical Immunization Safety Assessment (CISA) planned to address a data safety gap regarding use of LAIV4 vaccine in children with asthma by conducting a 3-site randomized, non-inferiority prospective study. The main goal was to compare the safety of LAIV4 versus IIV4 in children 5-11 years with persistent asthma during the 2016-2017 influenza season. CDC and the CISA study sites developed a protocol and associated materials, and were poised to begin enrollment early during the 2016-2017 influenza season. However, after the June 22, 2016 Advisory Committee on Immunization Practices (ACIP) vote recommending against use of LAIV4 during the 2016-2017 influenza season, CDC and study investigators decided to defer implementing a study using LAIV4 during the 2016-2017 influenza season. Investigators will reconsider initiating this study during the 2017-2018 influenza season if ACIP votes to reinstate LAIV4 use or new data become available; ACIP makes recommendations annually.

The planned LAIV4 study had unique features in its design that previously had not been implemented in vaccine safety studies, including: 1) enrolling a substantial proportion of children with moderate-severe asthma 2) using digital peak flow meters and 3) collecting clinical data through multiple, complementary, measures for 42 days after vaccination. To capitalize on progress made during development of the study protocol and associated documents and procedures, CISA is proposing to carry out a study at the three sites to assess the feasibility of recruiting, enrolling, retaining, and collecting clinical data on children 5-11 years with persistent asthma of varied levels of severity in an influenza vaccine safety study. Findings from this proposed feasibility study will facilitate improving the LAIV4 study in the future if it goes forward through the CISA Project or in another venue. In 2016-2017 season, FDA approved a new influenza vaccine for use in persons aged 4 years and older, Flucelvax® Quadrivalent (ccIIV4); ACIP incorporated this vaccine into its recommendations for the 2016-2017 influenza season. Therefore ccIIV4 will be used in place of LAIV4 for this feasibility study. There is no evidence that Flucelvax® increases the risk of wheezing in asthmatic children. The feasibility study also offers an opportunity to gain some additional descriptive safety data for this new vaccine in asthmatic children.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)
Actual Study Start Date : October 10, 2016
Actual Primary Completion Date : February 1, 2017
Actual Study Completion Date : February 1, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Flu Flu Shot

Arm Intervention/treatment
Active Comparator: IIV4
0.5 mL intramuscular injection
Drug: IIV4
Other Name: Fluarix

Active Comparator: cc IIV4
0.5 mL intramuscular injection
Drug: ccIIV4
Other Name: Flucelvax




Primary Outcome Measures :
  1. Feasibility Benchmark: Number of Parents That Complete the Memory Aid 1. [ Time Frame: 15 days ]
    Memory aid 1 is a diary completed by the subjects Parent. Daily symptoms, peak flow and requires the parent to record daily symptoms, peak flow, days, post-vaccination asthma clinical symptoms and symptom scores, adverse event, fever and concomitant medication administration data for 14 days (until day 15) after vaccination.

  2. Feasibility Benchmark: Number of Parent Completing Collection of Adverse Event Data [ Time Frame: Day 16 to 43 ]
    Parent will collect the following data: need for new prescription or nonprescription medications for the control of asthma, an unscheduled healthcare provider visit or consultation within 42 days after vaccination, any other clinically significant event occurring at any point during the study period. Serious Adverse Events (SAEs) will also be monitored through 42 days after vaccination and will include events that result in death, were life threatening, result in subject hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity. Additionally, important medical events that may not have resulted in death, were not life threatening, or did not require hospitalization might be considered SAEs when, according to appropriate medical judgment, they jeopardize the patient or subject and require medical or surgical intervention to prevent one of the outcomes listed above.

  3. Feasibility Benchmark: Number of Parents That Perform and Document All Home Digital Peak Flow Measurements [ Time Frame: 15 days ]
    Number of parents that perform and document all home digital peak flow measurements at least 11 days out of the 15-day monitoring period.

  4. Feasibility Benchmark: Number of Parents That Perform and Document the Digital Peak Flow for Day 42 [ Time Frame: Day 42 ]
    Parent will perform and document the digital peak flow for Day 42

  5. Feasibility Benchmark: Number of Parents That Document Nighttime Awakenings [ Time Frame: 15 days ]
    Number of parents that document nighttime awakenings for at least 11 of the 15-day monitoring period.

  6. Feasibility Benchmark: Number of Parents That Respond to Day 4 Call and Provide Requested Data [ Time Frame: Day 3 to 6 ]
    Number of parents that respond to Day 4 ( -1 day or + 2 days) call and provide requested data

  7. Feasibility Benchmark: Number of Parents That Respond to Day 8 Call and Provide Requested Data. [ Time Frame: Day 8-10 ]
    Number of parents that respond to Day 8 (plus 2 days) call and provide requested data.

  8. Feasibility Benchmark: Number of Parents That Respond to Day 15 Call and Provide Requested Data [ Time Frame: Day 14 to 17 ]
    Number of parents that respond to Day 15 (minus 1 or plus 2 days) call and provide requested data

  9. Feasibility Benchmark: Number of Parents That Respond to Day 29 Call and Provide Requested Data. [ Time Frame: Day 29-31 ]
    Number of Parents that respond to Day 29 ( Plus 2 Days) call and provide requested data.

  10. Feasibility Benchmark: Number of Parents That Respond to Day 44 Call [ Time Frame: Day 44-47 ]
    Number of parents that respond to Day 44 ( Plus 3 Days) call and provide requested data.

  11. Feasibility Benchmark: Number of Parents Completing a Satisfaction Survey [ Time Frame: 42 days ]
    Parent of each participant will be asked to complete a at the end of the study


Secondary Outcome Measures :
  1. Severe Local Reactogenicity Events During the 14 Days Post-vaccination [ Time Frame: 14 days ]
    Number of severe local reactogenicity events for 14 days after vaccination between recipients of ccIIV4 and IIV4.

  2. Severe Systemic Reactogenicity Events During the 14 Days Post-vaccination [ Time Frame: 14 days ]
    Number of solicited severe (not serious) systemic reactogenicity events for 14 days after vaccination between recipients of ccIIV4 and IIV4.

  3. Unsolicited and Severe Adverse Events [ Time Frame: 42 days ]
    The nature and frequency of the unsolicited and Severe adverse events will be described in children receiving ccIIV4 and IIV4 during the 42 days after vaccination.

  4. Number of Asthma Exacerbations Requiring Steroids [ Time Frame: 42 days ]
    For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 42 days post-vaccination (until day 43) for which the patient receives a new prescription for systemic corticosteroids..

  5. Number Participants With Asthma Exacerbations Requiring Medical Attention [ Time Frame: 42 days ]
    For the purpose of this study, asthma exacerbation will be defined as: any acute episode of progressively worsening shortness of breath/dyspnea, cough, wheezing, chest tightness, and/or respiratory distress during the 42 days post-vaccination (until day 43) for which the patient seeks unscheduled medical attention (e.g., healthcare provider office or Emergency Department visit or hospitalization)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children between 5-11 years of age, inclusive, at enrollment.
  • Participant must have a current diagnosis of persistent asthma.
  • Parent/legal guardian must provide written informed consent and subject must provide assent as appropriate for age prior to initiation of study procedures and according to local Institutional Review Board (IRB) requirement.
  • Parent/legal guardian and subject must be willing and able to comply with planned study procedures and be available for all study visits.
  • Children aged 5-8 years must have received at least 2 doses of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season. Children 9-11 years must have received at least 1 dose of seasonal trivalent or quadrivalent influenza vaccine prior to the current influenza season.
  • Is in good health, other than their asthma, as determined by medical history and targeted physical examination based on medical history.
  • English or Spanish literate.
  • Intention of being available for entire study period and complete all relevant study procedures, including follow-up phone calls and collection of information.

Exclusion Criteria:

  • Acute illness and/or a reported oral temperature of ≥ 100.4°F within 72 hours prior to enrollment (this may result in a temporary delay of vaccination.
  • Use of antipyretic medication during the preceding 24 hours that might mask a fever (temporary deferral).
  • History of a severe allergic reaction (e.g., anaphylaxis) to any component of study influenza vaccines or a known allergy to eggs.
  • Receipt of any licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to vaccination or planned receipt of any licensed vaccine within 42 days after vaccination.
  • Receipt of current year's licensed influenza vaccine.
  • Received an investigational agent (licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication) in the 28 days prior to enrollment or planned receipt before 42 days after vaccination.
  • Has immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
  • Has taken ≥ 20mg/day of prednisone or its equivalent, for 14 days or more within the past 28 days.
  • Has know active neoplasm or a history of any hematologic malignancy.
  • Has had a previous exacerbation of their asthma symptoms requiring systemic steroids within the prior 28 days, or has had a life-threatening exacerbation of asthma in the past two years (e.g. hypoxic seizure, mechanical ventilation).
  • History of Guillian-Barre syndrome within 6 weeks of previous influenza vaccination.
  • Has any condition that, in the opinion of the investigator, would interfere with the evaluation of the responses or would place the participant at unacceptable risk of injury.
  • Has any diagnosis, current or past, of schizophrenia, bipolar disease, or other major psychiatric disorder.
  • Currently taking aspirin or aspirin-containing products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02967393


Locations
Layout table for location information
United States, Georgia
Centers for Disease Control and Prevention
Atlanta, Georgia, United States, 30329
United States, North Carolina
Duke Clinical Vaccine Unit
Durham, North Carolina, United States, 27705
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Tennessee
Vanderbilt Vaccine Research Program
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
Centers for Disease Control and Prevention
Duke University
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Kathryn M Edwards, MD Vanderbilt Vaccine Research Program
  Study Documents (Full-Text)

Documents provided by Kathryn Edwards, Vanderbilt University Medical Center:
Layout table for additonal information
Responsible Party: Kathryn Edwards, Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT02967393    
Other Study ID Numbers: IIV4/LAIV4/CDC
First Posted: November 18, 2016    Key Record Dates
Results First Posted: April 23, 2018
Last Update Posted: April 23, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Asthma
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Bronchial Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases